pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,050 catalysts · 4,779 phase readout · 2,339 8k filing · 285 earnings · 271 pdufa · 166 phase 2 completion · 71 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase readout×type: pdufa×type: recall×clear all
type
  • phase readout4,779
  • 8k filing2,339
  • earnings285
  • pdufa271
  • phase 2 completion166
  • phase 1 completion71
phase 2 initiation
54
  • phase 1 initiation39
  • phase 1 2 completion33
  • phase 0 trial completion23
  • therapy area
    • Dermatology1
    • Infectious Disease1

    Date TBD

    50
    ›RECRUITINGphase readoutNCT07216196: The Feasibility of a Remote Problem-Solving Intervention for Autistic Adolescents or Young Adults and a Caregiver

    Sponsor: University of Missouri-Columbia. Phase: NA. Conditions: Autism

    full page →ctgov ↗
    ›WITHHELDphase readoutNCT07201896: [Trial of device that is not approved or cleared by the U.S. FDA]

    Sponsor: [Redacted]. Phase: . Conditions:

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT01511588: Hormonal Regulation of Puberty and Fertility

    Sponsor: National Institute of Environmental Health Sciences (NIEHS). Phase: . Conditions: Endocrine Disease, Infertility, Hypogonadism, Amenorrhea, Adolescents

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03114462: Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Malignant Neoplasms of Respiratory and Intrathoracic Organs, Squamous Cell Carcinoma of the Larynx

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07617246: The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer

    Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University. Phase: PHASE2. Conditions: Esophagus Cancer, Lung Cancer

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07621588: Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID

    Sponsor: Universidad Pontificia de Salamanca. Phase: NA. Conditions: Long COVID Syndrome, Post-Acute COVID-19 Syndrome

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06539988: Advancing Decisions About Virtual Service Encounters

    Sponsor: VA Office of Research and Development. Phase: NA. Conditions: Health Care Costs, Delivery of Health Care

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

    Sponsor: Biogen. Phase: PHASE2. Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07590388: Validation of the PRST Score Against Bispectral Index

    Sponsor: Gadjah Mada University. Phase: NA. Conditions: Elective Surgeries, General Anesthesia, BIS

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07622888: Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients

    Sponsor: Arma Ltd.. Phase: . Conditions: Gastrointestinal Dysfunction, Malnutrition, Delirium - Postoperative, Abdominal Neoplasm, Pelvic Neoplasm

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05398861: Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

    Sponsor: Henan Cancer Hospital. Phase: PHASE2. Conditions: HER-2 Negative Breast Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06930261: Dopaminergic Disruption Induced by Traumatic Coma: Dopaminergic Pathways Abnormalities and Biomarkers of Recovery Using MRI and 18F-LBT-999 PET

    Sponsor: Institut National de la Santé Et de la Recherche Médicale, France. Phase: PHASE2. Conditions: Coma, Traumatic

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT03895086: Fibromyalgia and Specific Physical Activity

    Sponsor: Centre Hospitalier Departemental Vendee. Phase: NA. Conditions: Fibromyalgia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07437183: A Multicenter Clinical Study on the Optimization of Timing and Efficacy Evaluation of Bronchoscopic Intervention in Pediatric Severe Pneumonia

    Sponsor: The Children's Hospital of Zhejiang University School of Medicine. Phase: NA. Conditions: Pediatric Sever Pneumonia

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07439783: Testing the CrOss Systems Technical Assistance for Retaining Staff (COSTARS) Model for Improving Staff Retention Among Child Welfare Workers and Peer Supporters, and Implementation of Evidence Based Interventions.

    Sponsor: Alicia Bunger. Phase: NA. Conditions: Substance Use Disorder, Opioid Use Disorder, Child Maltreatment, Implementation, Peer Recovery Supporters

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05127941: Andexanet Alfa: Non-interventional Study in Stroke Units in Germany (DE)

    Sponsor: University Hospital, Essen. Phase: . Conditions: Intracranial Hemorrhages

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07556354: Empowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City

    Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Blood Cholesterol, Blood Pressure Monitoring, Weight Change, BMI, Diabetes Education, Diabetes (DM)

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07236554: Blood Flow Restriction Training Versus Mulligan Technique in Treatment of Lateral Epicondylitis

    Sponsor: Cairo University. Phase: NA. Conditions: Lateral Epicondylitis (Tennis Elbow)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT06844305: Personalized Prosthetic Foot Prescription and Rehabilitation for Veterans With Lower Limb Loss

    Sponsor: Northwestern University. Phase: NA. Conditions: Amputation of Lower Limb

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07602205: Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A PROBE Clinical Trial

    Sponsor: Xuanwu Hospital, Beijing. Phase: NA. Conditions: CDKL5 Deficiency Disorder

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT04543994: Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

    Sponsor: The Cleveland Clinic. Phase: PHASE1. Conditions: Ulcerative Colitis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07107022: Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).

    Sponsor: Penumbra Inc.. Phase: . Conditions: Acute Ischemic Stroke (AIS)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07563829: NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

    Sponsor: NextPoint Therapeutics, Inc.. Phase: PHASE1. Conditions: Metastatic Malignant Neoplasm

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07609602: The Psychological Effects of Miscarriage Prediction Score: A Prospective Study

    Sponsor: King's College Hospital NHS Trust. Phase: NA. Conditions: Early Pregnancy Bleeding

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06935591: Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

    Sponsor: Vektor Medical. Phase: NA. Conditions: Atrial Fibrillation (AF)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07237191: Geriatric Distal Femur

    Sponsor: Wake Forest University Health Sciences. Phase: NA. Conditions: Articular Fractures

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03212274: Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

    Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04221750: Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors

    Sponsor: VA Office of Research and Development. Phase: PHASE3. Conditions: Frailty, Sarcopenic Obesity, Aging

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT07395518: A Randomized Controlled Trial Comparing the Incidence of Surgical Site Infections in Cesarean Section With and Without Subcutaneous Drain Placement at Queen Savang Vadhana Memorial Hospital

    Sponsor: Queen Savang Vadhana Memorial Hospital, Thailand. Phase: NA. Conditions: Surgical Site Infection (SSI)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07333118: A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

    Sponsor: Grit Biotechnology. Phase: EARLY_PHASE1. Conditions: Moderate to Severe Refractory Autoimmune Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT02926690: Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

    Sponsor: OncoTherapy Science, Inc.. Phase: PHASE1. Conditions: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07469397: Preliminary Exploration of Factors Affecting Complete Hemostasis and Supine Time After Removal of Femoral Arterial Sheath in ICU Patients

    Sponsor: National Taiwan University Hospital. Phase: . Conditions: Removal of Femoral Arterial Sheath in ICU Patients, Complete Hemostasis, Coronary Artery Disease, Percutaneous Coronary Intervention, Transcatheter Aortic Valve Implantation (TAVI)

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT04550897: A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients

    Sponsor: Oslo University Hospital. Phase: PHASE1. Conditions: Colorectal Cancer Metastatic

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06646497: Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years

    Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: PHASE2. Conditions: Aplastic Anemia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07423013: Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.

    Sponsor: Peking University Third Hospital. Phase: NA. Conditions: Thyroid Eye Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07454460: AYA-PeerConnect: A Communication Coaching Intervention for Adolescent/Young Adult Cancer Survivors (AYACS)

    Sponsor: Milton S. Hershey Medical Center. Phase: NA. Conditions: Communication, Anxiety, Depression, Social Isolation

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03467360: Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

    Sponsor: Centre Antoine Lacassagne. Phase: PHASE1. Conditions: Small Cell Lung Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06830720: A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

    Sponsor: Novartis Pharmaceuticals. Phase: . Conditions: Breast Neoplasms

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06612320: Refusal to Participate in a Randomized Trial Involving Pregnancy and Childbirth: Factors Associated With Refusal and Reasons for Refusal and Acceptance

    Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: . Conditions: Pregnancy Related

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06032923: Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

    Sponsor: National Heart, Lung, and Blood Institute (NHLBI). Phase: PHASE1. Conditions: Systemic Lupus Erythematosus (Sle)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03270059: Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

    Sponsor: OHSU Knight Cancer Institute. Phase: PHASE2. Conditions: Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the Brain

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT05644496: ZYNRELEF for Pain Management in Total Knee Arthroplasty

    Sponsor: Baptist Health South Florida. Phase: PHASE4. Conditions: Post Operative Pain, Osteoarthritis, Knee

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05556096: Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

    Sponsor: Alexion Pharmaceuticals, Inc.. Phase: PHASE3. Conditions: Generalized Myasthenia Gravis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06207396: Characteristics of Spiking in Ghent: a Multicentric Prospective Observational Study..

    Sponsor: University Hospital, Ghent. Phase: . Conditions: Intoxication, Unintended Ingestion of Product

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05966662: Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

    Sponsor: Shockwave Medical, Inc.. Phase: NA. Conditions: Coronary Artery Disease, Myocardial Infarction

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07403162: Cuevas Medek Exercises to Improve Postural Control and Balance in Children With Spastic Cerebral Palsy

    Sponsor: Riphah International University. Phase: NA. Conditions: Spastic Cerebral Palsy (sCP)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03747146: Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service

    Sponsor: Hospital for Special Surgery, New York. Phase: NA. Conditions: Anesthesia

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04924088: Medical-legal Partnerships to Prevent Evictions and Homelessness Among Veterans

    Sponsor: VA Office of Research and Development. Phase: NA. Conditions: Homelessness, Mental Health

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06971588: The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients

    Sponsor: Johns Hopkins University. Phase: NA. Conditions: Glaucoma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07506603: Kenya Preschool Study

    Sponsor: Yale University. Phase: NA. Conditions: Early Education, Early Childhood Development

    full page →ctgov ↗
    ← prev
    page 52 of 101
    next →